NCE-1 Intelligence & Market Opportunity

Miplyffa

Arimoclomol

Neuroprotective

Oral Capsules

Miplyffa is used to treat Niemann-Pick disease type C. The combination of the drug Miplyffa and miglustat is suggested for the treatment of neurological symptoms of Niemann-Pick disease type C in adults as well as children who are at least two years old.

Approval Date

20-Sep-24

NCE-1 Date

20-Sep-28

NCE Date

20-Sep-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

40.81%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

134

2027

213

2028

291

2029

342

2030

378

2031

418

2032

402

Molecule profile

Details & specifications

Molecule

Arimoclomol

Innovator

ZEVRA DENMARK AS

Dosage Form

Oral Capsules

Strength

47 mg, 62 mg, 93 mg and 124 mg

Therapeutic Category

Neuroprotective

Usage

To treat Niemann-Pick disease type C

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets